The DOI matches its Crossref record.
Prognostic significance of imaging contrast enhancement for WHO grade II gliomas
Open accessAbstract
In this study, we investigated the prognostic value of MRI contrast enhancement (CE) at the time of histological diagnosis specifically in a selected population of WHO grade II gliomas. We reviewed 927 histologically proven WHO grade II gliomas for which contrast-enhanced MR images were available at the time of histological diagnosis. CE patterns were classified into three categories: "patchy and faint," "nodular-like," and "ring-like." CE progression over time was recorded before oncological treatment on successive MR images, when available. CE was present in 143 cases (15.9%), with 93 patchy and faint, 50 nodular-like, and no ring-like patterns. CE areas were time progressive before oncological treatment in 35 of the 56 available cases (62.5%). Regardless of its pattern, the presence of CE was not significantly associated with a worsened prognosis (p = 0.415) by univariate analysis. Only the nodular-like pattern of CE (p < 0.01) and the time-progressive CE (p < 0.001) in the available subgroup proved to be statistically associated with survival since first oncological treatment. The present results show the necessity, in cases of WHO grade II gliomas, to study CE at the time of histological diagnosis and, whenever possible, to follow its progression over time before oncological treatment. Nodular-like CE and time-progressive CE are associated with a worsened prognosis, both suggesting malignant transformation, even though histopathological examination cannot initially disclose signs of malignancy in those areas.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
van den Bent, M., Wefel, J., Schiff, D., Taphoorn, M., Jaeckle, K., Junck, L., Armstrong, T., Choucair, A., Waldman, A., Gorlia, T., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70057-2 · Cited by 645
Guidelines on management of low‐grade gliomas: report of an EFNS–EANO* Task Force
Soffietti, R., Baumert, B. G., Bello, L., Von Deimling, A., Duffau, H., Frénay, M., Grisold, W., Grant, R., Graus, F., Hoang‐Xuan, K., et al. (2010) · European Journal of Neurology · doi:10.1111/j.1468-1331.2010.03151.x · Cited by 505
Self-citationCapelle, L., Fontaine, D., Mandonnet, E., Taillandier, L., Golmard, J. L., Bauchet, L., Pallud, J., Peruzzi, P., Baron, M. H., Kujas, M., et al. (2013) · Journal of Neurosurgery · doi:10.3171/2013.1.jns121 · Cited by 422
Self-citationEpileptic seizures in diffuse low-grade gliomas in adults
Pallud, J., Audureau, E., Blonski, M., Sanai, N., Bauchet, L., Fontaine, D., Mandonnet, E., Dezamis, E., Psimaras, D., Guyotat, J., et al. (2014) · Brain · doi:10.1093/brain/awt345 · Cited by 380
Self-citationMRI features predict survival and molecular markers in diffuse lower-grade gliomas
Zhou, H., Vallières, M., Bai, H. X., Su, C., Tang, H., Oldridge, D., Zhang, Z., Xiao, B., Liao, W., Tao, Y., et al. (2017) · Neuro-Oncology · doi:10.1093/neuonc/now256 · Cited by 354
Metadata
- Authors
- Pallud, J., Capelle, L., Taillandier, L., Fontaine, D., Mandonnet, E., Guillevin, R., Bauchet, L., Peruzzi, P., Laigle-Donadey, F., Kujas, M., Guyotat, J., Baron, M.-H., Mokhtari, K., & Duffau, H.
- Venue
- Neuro-Oncology
- Publisher
- Oxford University Press (OUP)
- Published
- 2009-04-01
- Volume
- 11
- Issue
- 2
- Pages
- 176-182
- ISSN
- 1522-8517 (ISSN-L)
- 1523-5866
- OpenAlex
- W2143099274
- Cited by
- 200
- References
- 0
- FWCI
- 3.18
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Prognostic significance of imaging contrast enhancement for WHO grade II gliomas. https://app.cochat.ai/papers/10.1215/15228517-2008-066
- The paper
- Pallud, J., Capelle, L., Taillandier, L., Fontaine, D., Mandonnet, E., Guillevin, R., Bauchet, L., Peruzzi, P., Laigle-Donadey, F., Kujas, M., Guyotat, J., Baron, M.-H., Mokhtari, K., & Duffau, H. (2009). Prognostic significance of imaging contrast enhancement for WHO grade II gliomas. Neuro-Oncology. https://doi.org/10.1215/15228517-2008-066
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.